Literature DB >> 21465311

Suppression of T-cell expansion by melanoma is exerted on resting cells.

Andrew J Russ1, Lucy Wentworth, Kyle Xu, Alexander Rakhmilevich, Christine M Seroogy, Paul M Sondel, M Suresh, Clifford S Cho.   

Abstract

BACKGROUND: Immunotherapeutic cancer protocols often rely on the ability to promote proliferative expansion of tumor-specific T-cell, but the influence of cancer on in vivo T-cell expansion remains largely undefined.
METHODS: The ability of control and B16F10 melanoma-bearing C57BL/6 mice to expand lymphocytic choriomeningitis virus antigen-specific T-cell populations in response to acute viral infection was compared by using flow cytometric assays of splenocytes.
RESULTS: The ability to expand virus-specific CD8+ and CD4+ T-cells was globally and markedly suppressed in tumor-bearing mice. Expanded cytotoxic T lymphocytes (CTLs) retained in vivo and in vitro functionality, suggesting that melanoma growth did not induce T-cell anergy. The magnitude of suppressed proliferative expansion was proportional to the extent of tumor burden. Melanoma-induced suppression of CTL expansion was correlated with upregulated apoptotic activity and hampered the induction of memory precursor effector cells. Adoptive transfer of resting LCMV antigen-specific T-cells before or after tumor establishment demonstrated that a critical period of in vivo exposure of resting T-cells to growing melanoma was responsible for the induction of suppressed expansion. This suppression was durable; surgical resection of melanoma after in vivo exposure to resting T-cells but before antigenic stimulation did not restore full expansion.
CONCLUSIONS: These data suggest that growing melanoma tumors exert a global, antigen-independent influence on resting T-cells that fundamentally reprograms their ability to undergo proliferative expansion in response to subsequent antigenic stimulation. This finding may have direct implications for T-cell-based immunotherapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21465311      PMCID: PMC4167760          DOI: 10.1245/s10434-011-1667-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo.

Authors:  Jason M Grayson; Laurie E Harrington; J Gibson Lanier; E John Wherry; Rafi Ahmed
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

2.  Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma.

Authors:  D C Lockhart; A K Chan; S Mak; H G Joo; H A Daust; A Carritte; C C Douville; P S Goedegebuure; T J Eberlein
Journal:  Surgery       Date:  2001-06       Impact factor: 3.982

Review 3.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

Review 4.  Less yin, more yang: confronting the barriers to cancer immunotherapy.

Authors:  Gregory Lizée; Mayra A Cantu; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 5.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

Review 6.  Tumors as elusive targets of T-cell-based active immunotherapy.

Authors:  Francesco M Marincola; Ena Wang; Meenhard Herlyn; Barbara Seliger; Soldano Ferrone
Journal:  Trends Immunol       Date:  2003-06       Impact factor: 16.687

7.  The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.

Authors:  Sheila A Caldwell; Mary H Ryan; Elwood McDuffie; Scott I Abrams
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

8.  Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.

Authors:  Erika A Danna; Pratima Sinha; Mileka Gilbert; Virginia K Clements; Beth A Pulaski; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.

Authors:  Susan M Kaech; Joyce T Tan; E John Wherry; Bogumila T Konieczny; Charles D Surh; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-11-16       Impact factor: 25.606

Review 10.  Adoptive cell therapy for the treatment of patients with metastatic melanoma.

Authors:  Steven A Rosenberg; Mark E Dudley
Journal:  Curr Opin Immunol       Date:  2009-03-21       Impact factor: 7.486

View more
  9 in total

1.  Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion.

Authors:  Andrew J Russ; Kyle Xu; Lucy Wentworth; Sheeba Alam; Justin V Meyers; Michael D Macklin; Alexander L Rakhmilevich; Victoria Rajamanickam; M Suresh; Clifford S Cho
Journal:  Cell Immunol       Date:  2011-06-17       Impact factor: 4.868

2.  Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Authors:  Amanda Contreras; Siddhartha Sen; Andrew J Tatar; David A Mahvi; Justin V Meyers; Prakrithi Srinand; Marulasiddappa Suresh; Clifford S Cho
Journal:  Cancer Immunol Immunother       Date:  2016-03-24       Impact factor: 6.968

3.  Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.

Authors:  David A Mahvi; Justin V Meyers; Andrew J Tatar; Amanda Contreras; Marulasiddappa Suresh; Glen E Leverson; Siddhartha Sen; Clifford S Cho
Journal:  J Immunother       Date:  2015 Feb-Mar       Impact factor: 4.456

4.  Memory T cells are uniquely resistant to melanoma-induced suppression.

Authors:  Lucy Wentworth; Justin V Meyers; Sheeba Alam; Andrew J Russ; M Suresh; Clifford S Cho
Journal:  Cancer Immunol Immunother       Date:  2012-08-04       Impact factor: 6.968

5.  Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.

Authors:  Edmund K Moon; Liang-Chuan Wang; Douglas V Dolfi; Caleph B Wilson; Raghuveer Ranganathan; Jing Sun; Veena Kapoor; John Scholler; Ellen Puré; Michael C Milone; Carl H June; James L Riley; E John Wherry; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2014-06-11       Impact factor: 12.531

6.  Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.

Authors:  Amanda Contreras; Megan V Beems; Andrew J Tatar; Siddhartha Sen; Prakrithi Srinand; M Suresh; Tahra K Luther; Clifford S Cho
Journal:  J Immunother Cancer       Date:  2018-05-29       Impact factor: 13.751

7.  Japanese Kampo Medicine Juzentaihoto Improves Antiviral Cellular Immunity in Tumour-Bearing Hosts.

Authors:  Shun Takaku; Masumi Shimizu; Rimpei Morita
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-13       Impact factor: 2.650

8.  Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008.

Authors:  Liangjian Lu; Haixi Yan; Vijay Shyam-Sundar; Tobias Janowitz
Journal:  Drug Des Devel Ther       Date:  2014-09-27       Impact factor: 4.162

9.  Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy.

Authors:  Shibin Qu; Tejaswi Worlikar; Amy E Felsted; Anutosh Ganguly; Megan V Beems; Ryan Hubbard; Ashley L Pepple; Alicia A Kevelin; Hannah Garavaglia; Joe Dib; Mariam Toma; Hai Huang; Allan Tsung; Zhen Xu; Clifford Suhyun Cho
Journal:  J Immunother Cancer       Date:  2020-01       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.